Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT02832245

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Computerized Registry of Patients With Venous Thromboembolism (RIETE) — Recruiting • Oncology • NCT02832245.

📅 14 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT02832245
Sponsor
Manuel Monreal
Start
2001-03
ClinicaliQ Trial Snapshot
  • Computerized Registry of Patients With Venous Thromboembolism (RIETE) — Recruiting • Oncology • NCT02832245.
  • What is being tested: RIETE is a computerized registry prospectively collecting extensive clinical data on consecutive patients diagnosed with venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, to establish real-world evidence on disease patterns, management practices, and outcomes.
  • Patient eligibility overview: The registry enrolls consecutive patients with confirmed venous thromboembolism across multiple healthcare settings; whilst specific inclusion/exclusion criteria are not detailed in this summary, the multidisciplinary nature suggests enrollment spans primary care through secondary care with diverse patient populations.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with…

Eligibility Snapshot
  • : * Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and/or superficial venous thrombosis) by objective tests. * Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Expert team to drive improvements in cancer care
Oncology · NHS England · 20 Sep 2026
Government establishes National Cancer Board to coordinate and drive improvements across cancer care services in the UK Board's inaugural meeting today (21…
View brief →
Clinical Brief
The Irish international rugby ‘trailblazer’ and her legacy of cancer awareness
Oncology · BBC Health · 30 Sep 2026
A prominent Irish rugby player's death from breast cancer highlights the importance of raising awareness about symptoms among younger women, even in…
View brief →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 09 Sep 2026
The International Agency for Research on Cancer (IARC) has classified drinking "very hot" beverages (>65°C) as a probable carcinogen (Group 2A), associated…
View brief →